by Developing a complex synthetic molecule is very different from producing a conventional active pharmaceutical ingredient (API). Multi-step synthesis, difficult reaction conditions, impurity control, high-potency compounds, specialized purification, and scale-up can all create challenges when a molecule moves from the laboratory to commercial production.
That is where Contract Development and Manufacturing Organizations (CDMOs) become important. The right CDMO can help a pharmaceutical or biotechnology company move from route scouting and process development to clinical manufacturing and commercial-scale API production.
According to Towards Healthcare, small-molecule API manufacturing increasingly requires specialized expertise in areas such as complex chemistry, HPAPI handling, continuous manufacturing, particle engineering, impurity profiling, and advanced analytical testing.
So, which CDMOs stand out for complex synthetic molecule manufacturing?
Leading CDMOs for Complex Synthetic Molecules
Towards Healthcare identifies several global CDMOs with capabilities across complex small-molecule API development and manufacturing. Among the notable names are Lonza, WuXi STA, Cambrex, Piramal Pharma Solutions, CordenPharma, Evonik Healthcare, Siegfried, Curia, Almac Group, Seqens, Axplora, Thermo Fisher Scientific/Patheon, SK pharmteco, Sterling Pharma Solutions, and EUROAPI.
1. Lonza
Lonza is one of the major names in complex API manufacturing, particularly for highly potent and technically demanding molecules.
Towards Healthcare highlights Lonza’s experience in HPAPI manufacturing, along with capabilities covering particle engineering, continuous manufacturing, and specialized low-dose handling. The company has also been expanding its capabilities for complex and highly potent APIs and ADC payload-linkers.
For sponsors developing oncology therapies or other potent compounds, these capabilities can be particularly valuable.
2. WuXi STA
WuXi STA has developed a broad platform for small molecules and complex modalities.
Towards Healthcare highlights its expertise in oligonucleotides, peptides, complex conjugates, oral solid manufacturing, and continuous purification, supported by a global network of R&D and manufacturing sites.
Its integrated approach allows sponsors to work with one partner across different stages of development and manufacturing.
3. Cambrex
Cambrex focuses heavily on small-molecule APIs and advanced chemistry.
Towards Healthcare highlights capabilities including biocatalysis, continuous-flow chemistry, solid-state chemistry, analytical services, and commercial API manufacturing across the U.S. and Europe.
This combination is useful when a molecule requires process optimization before it can be efficiently manufactured at scale.
4. Piramal Pharma Solutions
Piramal Pharma Solutions provides integrated pharmaceutical development and manufacturing services across North America, Europe, and Asia.
Towards Healthcare highlights its end-to-end capabilities and specialized expertise in highly potent APIs, making it an important provider for complex pharmaceutical molecules.
5. CordenPharma
CordenPharma specializes in complex chemistry, peptide synthesis, HPAPI manufacturing, and large-scale production.
One of its notable strengths is its focus on highly contained manufacturing environments for potent compounds. Towards Healthcare highlights its SafeBridge-accredited facilities and capability to handle extremely low occupational exposure limits.
6. Evonik Healthcare
Evonik Healthcare brings together API manufacturing, complex drug-delivery technologies, and specialized pharmaceutical solutions.
Towards Healthcare also highlights its focus on sustainable manufacturing and the integration of digital and process-development technologies.
This makes the company relevant to sponsors looking beyond basic API production toward more specialized development and manufacturing solutions.
7. Siegfried
Siegfried provides integrated development and manufacturing services through a global network of facilities.
Towards Healthcare highlights its capabilities in small-molecule API production and its continued investment in additional capacity for complex molecules. In June 2026, Siegfried advanced its Minden, Germany site with 100 m³ of large-scale reactor capacity, alongside Industry 4.0 technologies and high-containment capabilities.
Other Important CDMOs
The landscape also includes several specialized providers.
Almac Group
Almac supports small molecules, peptides, and HPAPIs, with manufacturing capabilities spanning clinical development through commercial production. Its services also extend into packaging and genomic profiling.
Seqens
Seqens operates a European R&D and manufacturing network focused on APIs and complex chemistry. The company has also been investing in greener chemistry approaches and safer solvent alternatives.
Axplora
Axplora specializes in high-potency and complex small-molecule manufacturing. Towards Healthcare highlights its flow chemistry capabilities and ability to manage extreme reaction conditions, supporting the production of complex oncology APIs, linker-payloads, and ADC-related molecules.
Thermo Fisher Scientific / Patheon
Thermo Fisher Scientific’s Patheon supports small molecules alongside biologics, viral vectors, mRNA, and cell therapies.
Towards Healthcare highlights its Quick to Clinic and Quick to Care programs, designed to help innovators move development programs toward clinical and commercial stages.
SK pharmteco
SK pharmteco is expanding its capabilities across oncology APIs, peptides, small molecules, and ADC payload and linker development.
Towards Healthcare reports investments in peptide and small-molecule API manufacturing capacity in South Korea and the U.S.
Sterling Pharma Solutions
Sterling Pharma Solutions provides complex medicinal chemistry, process development, reference-standard synthesis, and HPAPI manufacturing.
Towards Healthcare highlights its substantial reactor capacity across the U.S., U.K., and Europe and its ability to handle high-potency compounds under controlled containment conditions.
EUROAPI
EUROAPI is a major European API manufacturer offering both API production and CDMO services.
Its infrastructure supports large-scale chemical synthesis as well as microbial fermentation, with manufacturing sites across several European countries.
Why Complex Molecules Are Challenging to Manufacture
Complex synthetic molecules can involve many individual manufacturing steps. Each step introduces another opportunity for variability, impurities, or yield loss.
Towards Healthcare identifies several major technical challenges, including:
- Multi-step synthesis
- Reaction optimization
- Purification
- Process chemistry
- Particle engineering
- Solid-state characterization
- Impurity profiling
- Analytical validation
- High-potency compound handling
For example, changing a reaction condition during scale-up can influence yield, impurity formation, heat transfer, or the final physical properties of an API.
This is why process chemistry expertise is so important. A reaction that works well in a laboratory flask does not automatically behave the same way in a large commercial reactor.
From Laboratory Chemistry to Commercial Manufacturing
A strong CDMO should ideally be able to support a molecule throughout its development journey.
Early Development
The process begins with route scouting and process development. Chemists evaluate different synthetic pathways, catalysts, solvents, reaction conditions, and purification strategies.
Clinical Manufacturing
Once the process is established, the CDMO must demonstrate reproducibility and control. Batch records, analytical testing, quality systems, and process controls become increasingly important.
Scale-Up
The process then moves from laboratory or pilot quantities toward larger manufacturing equipment. This is where heat transfer, mixing, reaction kinetics, purification, and equipment configuration can create new challenges.
Commercial Production
At commercial scale, the focus expands to validated processes, reliable raw-material supply, regulatory compliance, quality systems, and consistent batch production.
Towards Healthcare describes this progression from preclinical development through Phase I, Phase II, Phase III, and commercial API manufacturing as an important part of the clinical-to-commercial journey.
HPAPIs Are Increasing the Need for Specialized CDMOs
Highly potent active pharmaceutical ingredients are particularly challenging.
These compounds can require specialized containment, air-handling systems, isolators, and strict occupational exposure controls to protect both the product and manufacturing personnel.
Towards Healthcare notes that oncology therapeutics account for more than 70% of HPAPI industry revenue, highlighting the strong connection between complex oncology pipelines and specialized manufacturing requirements.
This is one reason CDMOs with established HPAPI infrastructure are becoming increasingly valuable to pharmaceutical and biotechnology companies.
Digital Technology Is Changing API Manufacturing
Complex chemistry is also becoming more technology-driven.
Towards Healthcare highlights the growing use of:
- Robotics
- Automated process controls
- Predictive analytics
- AI-supported reaction analysis
- Digital laboratory systems
- Manufacturing execution systems
- Cloud-based data platforms
These technologies can help manufacturers improve process consistency, identify potential problems earlier, and make better use of historical manufacturing data.
The goal isn’t simply to automate manufacturing. It is to create a more predictable, connected, and controllable production environment.
Sustainability Is Becoming Part of CDMO Selection
Pharmaceutical companies are also paying greater attention to how their APIs are manufactured.
Complex synthetic chemistry can involve significant quantities of solvents, energy, and chemical reagents. CDMOs are therefore exploring green chemistry, solvent recovery, waste reduction, biocatalysis, and more efficient processes.
Towards Healthcare highlights green chemistry and sustainable manufacturing as increasingly important areas within small-molecule API production.
For sponsors, sustainability can increasingly become part of the technical and commercial evaluation when selecting a CDMO.
Contact Us: https://www.towardshealthcare.com/contact-us
How Should Companies Choose a CDMO?
There is no universal “best” CDMO for every molecule.
The right partner depends on the compound’s chemistry, potency, manufacturing scale, therapeutic application, geographic requirements, and regulatory strategy.
Companies should evaluate:
Technical expertise: Can the CDMO handle the molecule’s chemistry and complexity?
Scale-up capabilities: Does it have the reactor sizes and equipment required for future production?
HPAPI infrastructure: Can it safely manufacture highly potent compounds if required?
Analytical capabilities: Can it identify and control impurities, polymorphs, and other critical quality attributes?
Quality systems: Does it have a strong cGMP and regulatory track record?
Supply-chain resilience: Can it maintain reliable access to critical raw materials?
Clinical-to-commercial continuity: Can the same partner support the program as volumes increase?
Towards Healthcare recommends assessing technical expertise, regulatory history, equipment capabilities, quality systems, supply-chain resilience, project management, and experience with similarly complex molecules when selecting an API CDMO.
What Does the Future Hold?
The next generation of drug candidates is becoming increasingly complex.
New Chemical Entities, high-potency APIs, targeted protein degraders, peptides, ADC payloads, and other advanced modalities can require specialized chemistry that is difficult and expensive to establish internally.
This is creating an important role for CDMOs that can provide development, scale-up, manufacturing, analytical support, regulatory expertise, and commercial supply under one coordinated framework.
Insights from Payal Rabde – bringing a strategic perspective to evolving healthcare trends and developments.
These figures reflect the growing importance of reliable and specialized manufacturing infrastructure as pharmaceutical pipelines become more sophisticated.
About Us
Pharma Geek is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
